Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib dosing regimens in first-line advanced EGFR-mutant NSCLC with brain metastases
ChiCTR2400085346Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of befotertinib in non-small cell lung cancer (NSCLC), brain metastases and Carcinomatous Meningitis (CM) (3 arms), sponsored by Henan Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2400085346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085346.